



sirona
biochem

CORPORATE UPDATE

SEPTEMBER 28, 2022

TSX-V: SBM

FSE: ZSB | OTC: SRBCF



FORWARD LOOKING STATEMENTS

Sirona Biochem cautions you that statements included in this presentation that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.

MESSAGE FROM THE **CEO**

The value of our deal with **AbbVie's Allergan Aesthetics**, particularly the substantial long-term royalty payments, provides us with a clear path to profitability. We structured the agreement based on comprehensive internal sales forecast on AbbVie's potential net sales for TFC-1067 **over the next 17 years.**

We at Sirona Biochem deliberately opted for a higher royalty payment percentage instead of a larger upfront payment. The board and the management made a unanimous decision to structure the agreement this way for the long-term benefit of the company and its shareholders.

We believe that with Sirona Biochem's breakthrough compound, TFC-1067, AbbVie's Allergan Aesthetics is extremely well positioned to capture a significant share of the \$8 billion hyperpigmentation market.

Howard J. Verrico, MD

Founder, Sirona Biochem
CEO and Chairman of the Board



AbbVie / SBM Deal

Sirona Biochem reiterates the significance of its recently signed deal with **AbbVie**, one of the **largest pharmaceutical companies** in the world. Through this agreement, Sirona Biochem stands to gain global reach and a steady substantive royalty income stream. The goal to transform the company to profitability was the number one priority of Sirona Biochem and is reflected in this deal.

A photograph of three scientists in a laboratory. A man in a white lab coat and glasses is on the left, looking towards a woman in the center. The woman is also in a white lab coat with the Sirona logo and is wearing gloves, holding a small vial. Another woman is on the right, working at a lab bench with various pieces of equipment. The background shows laboratory shelves with bottles and equipment.

The current gold standard for hyperpigmentation, hydroquinone, is gradually being banned worldwide due to its potential **cytotoxic properties**. TFC-1067 is now poised to replace it as the go-to active ingredient for **next-generation treatments**.

AbbVie / SBM Deal

- As an aesthetics deal, Sirona's board and management remain pleased with the value of growth and profitability of the company.
- The deal was negotiated with input from multiple industry experts at every step of the process, and long-term revenue generation was the focus of achieving maximum value for Sirona. Through royalty payments, AbbVie's anticipated commercial success will be shared with Sirona for many years.
- In 2019, prior to the acquisition by AbbVie, Allergan reported SkinMedica* sales of \$158M USD globally and a growth rate of 13.8% between 2018 and 2019.
- While AbbVie does not report publicly by segment, the portfolio of 'other aesthetics' contributed to global sales of \$1.5 Billion USD in 2021
- Partnering with AbbVie will give Sirona the ultimate global reach and will achieve the most sales for our active ingredient.
- Sirona will supply the ingredient under a separate agreement and will also receive a royalty on sales of all products containing TFC-1067.
- Sirona will leverage the success of this deal when meeting with institutional investors and analysts.
- Sirona worked with AbbVie on a successful clinical trial with TFC-1067, so there is no question that the compound is an excellent commercial active ingredient. With the formulation used in the clinical trial, 100% of participants stated the product was effective and they would purchase it.
- Summary: clinically proven safe, highly effective, partnered with a global leader and long-term royalty stream equals Sirona's commercial success.

**Allergan
Aesthetics**
an AbbVie company

*includes Latisse

STRATEGIC REVIEW

Sirona Biochem has recently completed the first stage of its strategic operational review to maximize corporate efficiency. The review was conducted by the management team and the company's **newly appointed advisory board member, Dr. Wolfgang Bieber**. They are now ready to move forward with optimizations, with a particular focus on Sirona Biochem's product pipeline.



• Dr. Bieber met with Sirona management and the TFChem team in France over several days.

- September began the strategic review of operations at Sirona and TFChem. Attended by Sirona's CEO and CFO, Dr. Bieber, Sirona's CSO and the entire team of scientists onsite, in person at our lab in France.
- Discussions are now taking place on equipment and staffing at the lab, as well as how to fully maximize the potential of the team and prioritize the pipeline.
- It is anticipated that Dr. Bieber will be meeting with the group on a regular schedule.



With the success of the **licensing deal with AbbVie** the company needs to prepare for its next phase of growth. Dr. Bieber plans to implement a review of current management, including the acquisition of new talent to bolster the company's research and development operations. Further, he will be putting extensive focus on **Sirona's promising pharmaceutical pipeline** by exploring partnerships with major international players in the sector.

In my professional opinion, as a chemist of over three decades, I've seldom seen anything like **Sirona's technology platform**, which is undoubtedly revolutionary in terms of its potential to **provide lasting solutions** to current and future pharmaceutical obstacles.

Dr. Wolfgang Bieber

TFC-1326 - Anti-Aging

TFC-1326 is Sirona Biochem's next big breakthrough, backed by strong clinical data and years of research. The formulation design for the anti-ageing compound has been completed, and the team is now moving forward with conducting clinical trials. The Anti-Aging market is forecasted to reach \$271 billion by 2024*.



- Sirona and TFChem team assessing the new formulation of TFC-1326 at their lab in France.

Sirona has made **significant advances** in the formulation of TFC-1326. Management feels **confident in the success** of the upcoming safety and human trials.



TFC-1326 - Anti-Aging

The anti-aging project is one of our most exciting, spanning many years and millions of dollars in research. The preclinical data is strong, and the commercial potential is massive. This product is considered to have one of the **highest commercial potentials** of any project undertaken by Sirona.

- TFC-1326 has the potential to truly reverse the visible aging of the skin by restoring lost skin volume that occurs with the aging process with multiple mechanisms of action unlike any existing product commercially available.
- Safety studies in humans have begun in preparation for the efficacy clinical trial.
- Scale-up of the compound is in its final stages in China.
- Formulation design has been completed.
- The trial is scheduled to begin in the last (calendar) quarter of 2022 and will run for 12 weeks, with results expected in early 2023. The trial will measure multiple parameters of the aging process using a leading clinical trial company in Paris, France. The parameters were carefully selected to provide maximal analysis and reviewed externally to make sure potential future partners have the data they desire.
- Sirona will aim to finalize our partnership discussions for a right of first refusal prior to the commencement of the trial.

TFC-039 - Anti-Diabetes

TFC-039 is Sirona Biochem's novel SGLT2 inhibitor compound, which is showing promising results for both **animal and human applications**. Studies are now being conducted for possible applications in treating **chronic kidney disease**. Sirona Biochem is currently in talks with four major pharmaceutical companies to further develop and commercialize the compound.

Sirona intends to be one of the first companies **to offer a solution** to the growing risk of type-2 diabetes in animals.



TFC-039 - Anti-Diabetes

TFC-039 Animal Health

- Several animal health companies remain interested in licensing the SGLT2 inhibitor compound, TFC-039.
- Due diligence is proceeding and Wanbang biopharmaceuticals is committed to providing all data generated during their Phase I clinical trials. Cooperation is established at the highest levels of both companies with regular meetings and very frequent communications.
- Wanbang and Sirona will continue to work together to complete a high-value agreement in 2022.
- SGLT2 inhibitors are also now being looked at to treat chronic kidney disease (CKD) in humans. CKD is also very common in cats. It is estimated that 20-50% of cats over 15 years will have some degree of CKD. Potential use in treating heart disease is being initiated in humans and is being explored in cats.

TFC-039 Human Diabetes

- Sirona Biochem is in due diligence with a new potential partner to develop TFC-039 for use in humans.


TFC-039 Other Indication

- The company is also developing a strategy around a new indication for TFC-039.
- Details of the new indication will not be disclosed until patents have been completed.

Anti-Cellulite, Keloid and Scar Therapy

Sirona Biochem has identified several novel compounds currently in early-stage discovery and development for treating scars, keloids, and cellulite. This new project represents an important step forward in achieving the company's planned pipeline expansion.

- Potential compounds have been selected for further development from our novel library of compounds.
- The company is still in the early stages of planning these projects and they represent important goals in our pipeline expansion.



Anti-Viral

- Sirona is completing details of the testing done in Europe. The goal is to collaborate with this institution for future scientific work on the project.
- Testing is still expected to start in H2 of 2022.
- The antiviral market is estimated to reach \$64 B US by 2028.
- The lab continues building a library of potential compounds to maximize the opportunity and build strong IP.



The need for **new antivirals** remains incredibly strong as vaccines struggle to combat continually evolving viruses like the SARS-CoV-2 virus

TFChem - Laboratory Upgrades

Sirona Biochem has recently made significant upgrades to its facility in France. The company **added a Nuclear Magnetic Resonance Spectrometer (NMR)**, which now allows it to identify the structures of organic compounds at extremely low temperatures. Having specialized spectroscopy available in-house, enables Sirona Biochem to **accelerate its research and development** of novel compounds and rapidly expand its product pipeline.



About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.

For more information regarding this press release, please contact:

Investor Enquiries:


Jonathan Williams

Managing Director

Momentum PR

Phone: 1.450.332.6939

Email: jwilliams@momentumpr.com



sirona
biochem

TSX-V: SBM
FSE: ZSB | OTC: SRBCF